Clinical Trials Logo

Filter by:
NCT ID: NCT02217813 Completed - Healthy Volunteers Clinical Trials

A Bioequivalence Study Comparing Two Different Tafamidis Formulations

Start date: October 2014
Phase: Phase 1
Study type: Interventional

Each subject will be given tafamidis. After swallowing a single tafamidis capsule, tafamidis blood concentrations will be measured periodically for one week. After about 20 days, subjects will take a different form of tafamidis capsule and the process repeated. Tafamidis concentrations from the two different formulations will be compared to determine if they are approximately the same.

NCT ID: NCT02217787 Completed - Healthy Clinical Trials

Food Effect Study for PF-06372865

Start date: September 2014
Phase: Phase 1
Study type: Interventional

This study has been designed to investigate the effect of high fat food on the pharmacokinetics of PF-06372865 when administered to healthy subjects as single oral doses.

NCT ID: NCT02217475 Completed - Clinical trials for Nonalcoholic Steatohepatitis

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

CENTAUR
Start date: September 18, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether cenicriviroc is effective and safe in the treatment of nonalcoholic steatohepatitis (NASH) in adult participants with liver fibrosis.

NCT ID: NCT02216578 Completed - Clinical trials for Metastatic Gastrointestinal Stromal Tumor

Ph II CABOGIST in GIST

Start date: February 2, 2017
Phase: Phase 2
Study type: Interventional

The study is a multi-center, multi-national, open label, single arm Phase II study of single-agent cabozantinib. The objective of the study is to assess the safety and activity of cabozantinib in patients with metastatic GIST who have previously progressed on imatinib and sunitinib and have not been exposed yet to other KIT- or PDGFR-directed tyrosine kinase inhibitors. Patient will receive cabozantinib until they experience no further benefit from the treatment, becoming intolerant to the drug or wishing to discontinue the treatment. Treatment beyond RECIST 1.1 progression is allowed in patients deriving clinical benefit upon investigator's discretion, provided no other criteria for treatment withdrawal are met.

NCT ID: NCT02214134 Completed - Clinical trials for Any Stage of Lung Cancer (Any Histotype)

SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access

SPECTAlung
Start date: May 22, 2015
Phase:
Study type: Observational [Patient Registry]

SPECTAlung is a program aiming at screening patients with thoracic tumors to identify the molecular characteristics of their disease. The thoracic tumors include lung cancer, malignant pleural mesothelioma, thymoma or thymic carcinoma at any stage. Once the molecular characteristics are identified, there might be the possibility to offer these patients access to targeted clinical trials.

NCT ID: NCT02213263 Completed - Follicular Lymphoma Clinical Trials

A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

Start date: September 30, 2014
Phase: Phase 3
Study type: Interventional

This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is similar to that of rituximab-EU.

NCT ID: NCT02212626 Completed - Clinical trials for Peripheral Vascular Disease

Prospective, Non-randomized Multi-center, Controlled Physician-initiated Trial: Rotarex Belgium In-stent Occlusion

ROBINSON
Start date: August 2014
Phase: Phase 4
Study type: Interventional

The objective of this study is to evaluate the safety and efficacy of recanalization of acute and subacute femoropopliteal stent occlusions with the Rotarex S catheter (Straub Medical)

NCT ID: NCT02211846 Completed - Overactive Bladder Clinical Trials

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Start date: September 21, 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics as well as the safety and tolerability of mirabegron OCAS tablets after single-dose administration at different dose levels in children and adolescents with NDO or OAB.

NCT ID: NCT02211716 Completed - Clinical trials for Peripheral Vascular Disease

Physician-Initiated Trial Investigating the BeGraft Peripheral Stent Graft System

Start date: June 2014
Phase: Phase 4
Study type: Interventional

The objective of this clinical investigation is to evaluate, in a controlled setting, the long-term (up to 12 months) safety and efficacy of the BeGraft Peripheral Stent Graft System (Bentley InnoMed) in clincial settings post CE-certification when used according to the indications of the IFU.

NCT ID: NCT02211664 Completed - Clinical trials for Peripheral Vascular Disease

Physician-Initiated Trial Investigating the Efficacy of Endovascular Treatment of Femoropopliteal Arterial Stenotic Disease With the Biotronik Passeo-18 Lux Drug Releasing Balloon and the Biotronik Pulsar-18 Stent (Comparing With 4EVER Trial Results)

BIOLUX 4EVER
Start date: June 2014
Phase: Phase 4
Study type: Interventional

The objective of this clinical investigation is to evaluate the short- and long-term (up to 24 months) outcome of treatment by means of dilation with the Passeo-18 Lux drug releasing balloon and by Pulsar-18 stent implantation in symptomatic (Rutherford 2-4) femoro-popliteal arterial stenotic or occlusive lesions.